Search our Database of Scientific Publications and Authors

I’m looking for a

    3671 results match your criteria Plaque Psoriasis

    1 OF 74

    Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis.
    Biopharm Drug Dispos 2018 Apr 21. Epub 2018 Apr 21.
    Auckland Clinical Studies Ltd, Auckland, New Zealand.
    This study evaluated pharmacokinetics (PK), efficacy, safety, and tolerability of bleselumab - a fully-human anti-CD40 monoclonal recombinant IgG4. Patients with moderate-to-severe psoriasis were randomized on Day 1 to receive bleselumab or placebo on Days 1, 15, and 29 in a dose-escalation of bleselumab 0.1, 0. Read More

    Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate to severe plaque psoriasis.
    J Dermatolog Treat 2018 Apr 20:1-20. Epub 2018 Apr 20.
    a Pharmacy Department , Hospital General Universitario Gregorio Marañón , Madrid , Spain.
    Purpose: The aim of this study was to identify clinical factors associated with dose reduction and dose escalation in the treatment with ustekinumab in patients with moderate to severe plaque psoriasis.

    Materials And Methods: An observational, longitudinal and retrospective study was conducted using patients with moderate to severe plaque psoriasis. We reviewed clinical histories and variables were recorded on a database (patients' characteristics, pharmacotherapeutics, effectiveness and safety). Read More

    Effects of Etanercept on the Patient-Perceived Results (PROs) in Patients with Moderate-To-Severe Plaque Psoriasis: Systematic Review of the Literature and Meta-Analysis.
    J Dermatolog Treat 2018 Apr 19:1-20. Epub 2018 Apr 19.
    c Dermatology Service, Infanta Leonor University Hospital , Madrid , Spain.
    Purpose: To evaluate the efficacy of etanercept (ETN) compared with placebo for moderate-to-severe psoriasis regarding patients reported outcomes (PROs).

    Methods: Systematic review of studies retrieved by a sensitive search strategy in Medline, Embase, Cochrane Library.

    Selection Criteria: (population) studies had to include patients with for moderate-to-severe psoriasis; (intervention and control) studies had to test ETN vs placebo; and (outcomes), studies had to report PROs including quality of life, pain, pruritus or sleep. Read More

    Evaluation of the effect of Pulsed Dye Laser on chronic Psoriatic plaque.
    J Dermatolog Treat 2018 Apr 18:1-23. Epub 2018 Apr 18.
    b Kafr Elzaeat General hospital Gharbia Egypt , Egypt.
    Psoriasis is one of the most prevalent immune mediated skin diseases. Selective vascular destruction by pulsed dye laser is considered one of effective laser treatments.

    Objective: Evaluation of the therapeutic effect of pulsed dye laser in treatment of chronic psoriatic plaque lesions and changes in human beta defensin-2 expression in the psoriatic patients before and after treatment, with correlation to the clinical improvement. Read More

    Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results Through 48 Weeks of a Phase 3, Multicenter, Randomized, Double-Blinded, Etanercept- and Placebo-Controlled Study (CIMPACT).
    J Am Acad Dermatol 2018 Apr 13. Epub 2018 Apr 13.
    University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
    Background: Phase 2 psoriasis studies with the Fc-free, PEGylated, anti-tumor necrosis factor biologic certolizumab pegol demonstrated meaningful clinical activity.

    Objective: Assess safety and efficacy of certolizumab in adults with moderate-to-severe chronic plaque psoriasis.

    Methods: Patients were randomized 3:3:1:3 to certolizumab 400 mg, 200 mg, or placebo every 2 weeks for 16 weeks or etanercept 50 mg twice-weekly for 12 weeks. Read More

    Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results through 48 Weeks from Two Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2).
    J Am Acad Dermatol 2018 Apr 13. Epub 2018 Apr 13.
    Dermatologikum Hamburg and SCIderm Research Institute, Hamburg, Germany.
    Background: Certolizumab pegol, the only Fc-Free, PEGylated anti-tumor necrosis factor biologic, demonstrated clinically meaningful improvements and suggested a positive risk-benefit balance in phase 2 studies in adults with moderate-to-severe chronic plaque psoriasis.

    Objective: Assess certolizumab efficacy and safety versus placebo in phase 3 studies.

    Methods: Patients with moderate-to-severe chronic plaque psoriasis were randomized 2:2:1 to certolizumab 400 mg, 200 mg, or placebo every 2 weeks. Read More

    Efficacy, Safety, and Potency of Betamethasone Dipropionate Spray 0.05%: A Treatment for Adults with Mild-to-moderate Plaque Psoriasis.
    J Clin Aesthet Dermatol 2018 Apr 1;11(4):14-22. Epub 2018 Apr 1.
    Drs Sidgiddi, Pakunlu, and Allenby are with Promius Pharma, a subsidiary of Dr. Reddy's Laboratories, in Princeton, New Jersey.
    A spray formulation of betamethasone dipropionate 0.05% (BD spray 0.05%; Sernivo™ [betamethasone dipropionate] Spray 0. Read More

    Efficacy and Safety of Ixekizumab Over 4 Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis.
    J Am Acad Dermatol 2018 Apr 10. Epub 2018 Apr 10.
    Eli Lilly and Company, Indianapolis, Indiana, United States of America.
    Background: Ixekizumab has demonstrated improvement in moderate-to-severe psoriasis patients by selectively targeting interleukin-17A, a pro-inflammatory cytokine important in psoriasis pathogenesis.

    Objective: To report 4-year efficacy and safety results from the open-label extension (OLE) of this phase 2 trial.

    Methods: Analysis was by last observation carried forward. Read More

    Secukinumab treatment in new-onset psoriasis: Aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study.
    J Eur Acad Dermatol Venereol 2018 Apr 6. Epub 2018 Apr 6.
    Novartis Pharma AG, Basel, Switzerland.
    Background: To date, biologic treatments have been assessed in subjects with a long-term history of psoriasis and previous failures to systemic and topical therapies. In rheumatoid arthritis and other immune-mediated inflammatory diseases, early intensive systemic treatment prolongs treatment-free remission. We hypothesize that by treating patients with psoriasis early with an effective systemic therapy, we may be able to alter the clinical outcome and the natural course of the disease. Read More

    Psoriasis patients' preference for an aerosol foam topical formulation.
    J Eur Acad Dermatol Venereol 2018 Apr 6. Epub 2018 Apr 6.
    SCRIPT, Toronto, ON.
    We read with interest the November 2017 article of Hong et al., reporting the experience of psoriasis patients in the PSO-INSIGHTFUL study, who used fixed-dose combination calcipotriol 50 μg/g and betamethasone dipropionate 0.5 mg/g (Cal/BMD) gel and aerosol foam formulations, each for 1 week. Read More

    Association of the novel susceptible locus rs9266150 with clinical features of psoriasis vulgaris in the Chinese Han population.
    Exp Dermatol 2018 Apr 6. Epub 2018 Apr 6.
    Institute of Dermatology and Department of Dermatology the first Affiliated Hospital, Anhui Medical University, Hefei, Anhui, 230032, China.
    Background: Psoriasis is a chronic multifactorial disease, and is considered to be strongly associated with the major histocompatibility complex (MHC) region. We have discovered an independent, novel and susceptible psoriasis risk HLA loci, rs9266150; P = 4.52 × 10 ) for the first time. Read More

    Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of two Phase 3 randomized controlled trials.
    J Am Acad Dermatol 2018 Mar 31. Epub 2018 Mar 31.
    Valeant Pharmaceuticals, Bridgewater, NJ 08807.
    Topical corticosteroids are the mainstay of psoriasis treatment; long-term safety concerns limit use. Combination with tazarotene may optimize efficacy, minimizing safety/tolerability concerns, In patients with moderate-to-severe plaque psoriasis treated with HP/TAZ lotion, improvement is noted within 2 weeks with few adverse effects observed after 8 weeks., HP/TAZ lotion may provide a realistic topical option for psoriasis management. Read More

    Practical Strategies for Optimizing Management of Psoriasis.
    Semin Cutan Med Surg 2018 Feb;37(2S):S52-S55
    Chairman, Division of Dermatology Baylor University Medical Center Dallas, Texas.
    Approximately 30% of patients with moderate plaque psoriasis and 20% of those with severe psoriasis have inadequate disease control with their current therapeutic regimens. Among the factors that affect treatment efficacy are drug selection and lack of patient adherence to treatment, which is often due to patient frustration that psoriasis is a chronic, multisystemic, and incurable disease. By forming a strong therapeutic alliance with patients and by asking them about their expectations for treatment, clinicians have a better chance of providing patients with more effective and durable relief from their psoriasis symptoms. Read More

    Common and Not-So-Common Comorbidities of Psoriasis.
    Semin Cutan Med Surg 2018 Feb;37(2S):S48-S51
    Director of Dermatology Research Department of Dermatology Kaiser Permanente Los Angeles Medical Center Los Angeles, California.
    Plaque psoriasis is increasingly recognized as a multisystemic disease whose most common comorbidities include psoriatic arthritis, cardiovascular disease, metabolic syndrome, overweight/obesity, inflammatory bowel disease, and depression. The presence of such comorbidities affects the therapeutic choices for clinicians. Patients often visit dermatologists more frequently than they do other clinicians, so it is incumbent upon dermatologists to recognize and address early signs of psoriatic comorbidities to prevent further deterioration and improve their patients' quality of life. Read More

    The Evolving Landscape of Psoriasis Treatment.
    Semin Cutan Med Surg 2018 Feb;37(2S):S39-S43
    Director of Dermatology Research Department of Dermatology Kaiser Permanente Los Angeles Medical Center Los Angeles, California.
    The process of discovering new drugs for plaque psoriasis has revealed much about the multisystemic nature of the disease. Current and emerging biologic agents may reliably achieve a Psoriasis Area and Severity Index (PASI 75) up to 90. Initially, clinicians select therapies based on the severity of the psoriasis. Read More

    Epidermal barrier and oxidative stress parameters improve during in 311 nm narrow band UVB phototherapy of plaque type psoriasis.
    J Dermatol Sci 2018 Mar 21. Epub 2018 Mar 21.
    Department of Dermatology and Allergy, Charité Universitätsmedizin, Berlin, Germany.
    Background: Psoriasis is a multi-systemic inflammatory disease that results from dysregulation between epidermal keratinocyte homeostasis and both innate and acquired immunity. Epidermal barrier defect has been described in psoriatic lesions. Furthermore an imbalance between pro-oxidative stress and antioxidant defense mechanisms are known in psoriasis patients. Read More

    Dual neutralization of both IL-17A and IL-17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded placebo-controlled phase 2b trial.
    J Am Acad Dermatol 2018 Mar 30. Epub 2018 Mar 30.
    Oregon Medical Research Center, Portland, OR, USA.
    Background: Neutralizing interleukin (IL)-17F in addition to IL-17A may provide a more complete and specific approach to inhibiting inflammation.

    Objective: Assess the efficacy and safety of bimekizumab, a monoclonal antibody that potently and selectively neutralizes IL-17A and IL-17F, in patients with moderate-to-severe plaque psoriasis.

    Methods: Double-blinded, placebo-controlled phase 2b study (NCT02905006). Read More

    Oral Candida colonization and plaque type psoriasis: Is there any relationship?
    J Investig Clin Dent 2018 Mar 30:e12335. Epub 2018 Mar 30.
    Department of Oral Disease and Diagnosis, Islamic Azad University, Tehran, Iran.
    Aim: The potential role of superantigens derived from microbial agents could be considered in the pathogenesis of psoriasis, but the association between Candida albicans and psoriasis severity is still controversial. The present study was designed to compare the prevalence of oral candidiasis in a group of psoriatic patients and healthy patients, and its correlation with psoriasis severity.

    Methods: Seventy psoriatic patients with no history of systemic treatment and 70 closely-matched control patients underwent oral examination. Read More

    Rapid onset of multiple concurrent squamous cell carcinomas associated with the use of an arsenic-containing traditional medicine for chronic plaque psoriasis.
    BMJ Case Rep 2018 Mar 30;2018. Epub 2018 Mar 30.
    Department of Dermatology, University of Medicine and Pharmacy of Ho Chi Minh City, Ho Chi Minh City, Vietnam.
    We report a case of a 46-year-old Vietnamese man who developed widespread, numerous and concurrent cutaneous squamous cell carcinomas (SCCs) in non-sun exposed skin areas after taking a traditional medicine (TM) formulation for chronic plaque psoriasis. The SCC lesions began to develop within 12-15 months after beginning the arsenic-containing TM. The patient experienced both acute and chronic symptoms consistent with arsenic exposure. Read More

    Psoriasiform Pemphigus Foliaceus in an African American Female: An Important Clinical Manifestation.
    J Drugs Dermatol 2018 Apr;17(4):471-473
    A 50-year-old African-American woman presented to the dermatology clinic with a pruritic eruption of 3 years' duration. On clinical examination, the patient had well-demarcated, pink, atrophic plaques and superficial erosions over the inframammary folds and mid-chest. She also had well-demarcated, hyperpigmented, hyperkeratotic scaly plaques over the abdomen, suprapubic region, elbows, knees, and back with sporadic small superficial blisters. Read More

    Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
    Am J Clin Dermatol 2018 Mar 29. Epub 2018 Mar 29.
    Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
    The article Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) written by Andrew Blauvelt. Read More

    The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients - preliminary report.
    Postepy Dermatol Alergol 2018 Feb 20;35(1):53-59. Epub 2018 Feb 20.
    Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, University of Warmia and Mazury, Olsztyn, Poland.
    Introduction: Methotrexate (MTX) has anti-proliferative and anti-inflammatory effects in psoriasis. Moreover, low doses can reduce the risk of developing cardiovascular diseases. It turns out that psoriasis and atherosclerosis have a similar pathogenetic mechanism: the same pro-inflammatory cytokines, Th1 and Th17, are involved in both diseases. Read More

    No Relation between Psoriasis and Renal Abnormalities: A Case-Control Study.
    ScientificWorldJournal 2018 11;2018:5301631. Epub 2018 Feb 11.
    Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
    Multiple observational studies have demonstrated that psoriasis is associated with nephropathy; however, the renal involvement in psoriasis remains largely a matter of debate. The current study was designed to investigate if psoriatic patients are at increased risk of renal abnormalities, in absence of any other comorbidities. Forty patients (11 women, 29 men, mean age 44. Read More

    Clinical and Therapeutic Aspects of Linear Psoriasis: A Study of 30 Cases.
    Am J Clin Dermatol 2018 Mar 29. Epub 2018 Mar 29.
    Service de Dermatologie, Hôpital Victor Dupouy, 69 rue du Lieutenant-Colonel Prud'hon, 95100, Argenteuil, France.
    Background: Psoriasis affects 2-4% of the population, with the most common clinical type being plaque psoriasis. The linear form of psoriasis is very rare. The literature on linear psoriasis (LP) consists of only case reports, and data are few. Read More

    Hypophysitis following Treatment with Ustekinumab: Radiological and Pathological Findings.
    Front Endocrinol (Lausanne) 2018 9;9:83. Epub 2018 Mar 9.
    Department of Endocrinology, Hospital Universitario de la Princesa, Instituto de Investigación Princesa, Universidad Autónoma de Madrid, Madrid, Spain.
    Context: Ustekinumab is a human IgG1 monoclonal antibody that targets interleukin (IL)-12 and IL-23, which may be useful in the treatment of autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn's disease. Hypophysitis is an immune-derived inflammatory condition of the pituitary gland that may lead to pituitary dysfunction. With the increasing use of immunotherapy, it is possible that this and other new immune-related adverse events (IRAEs) arise, although the mechanisms involved are still incompletely defined. Read More

    Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    JAMA Dermatol 2018 Mar 28. Epub 2018 Mar 28.
    Department of Dermatology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
    Importance: Patients with psoriasis enrolled in clinical trials of biologics may not be representative of the real-world population. There is evidence that patients ineligible for such trials have a greater risk of serious adverse events (SAEs), but the effect on drug discontinuation and effectiveness are unknown.

    Objective: To determine whether (1) drug discontinuation, (2) effectiveness, and (3) rates of SAEs differ in patients with psoriasis categorized as eligible or ineligible for clinical trials. Read More

    Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.
    Arch Dermatol Res 2018 Mar 24. Epub 2018 Mar 24.
    Psoriasis-Center at the Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Germany.
    Fumarates (fumaric acid esters, FAEs) are orally administered systemic agents used for the treatment of psoriasis and multiple sclerosis. In 1994, a proprietary combination of FAEs was licensed for psoriasis by the German Drug Administration for use within Germany. Since then, fumarates have been established as one of the most commonly used treatments for moderate-to-severe psoriasis in Germany and other countries. Read More

    Intra- and inter-observer variability of image-based PASI assessments in 120 patients suffering from plaque type psoriasis.
    J Eur Acad Dermatol Venereol 2018 Mar 23. Epub 2018 Mar 23.
    Department of Dermatology, University of Heidelberg, Germany.
    Background: The Psoriasis Area and Severity Index (PASI) is the standard for psoriasis severity assessment. However, PASI measurement is complex and subjective, frequently leading to a high intra- and inter-observer variability. To date, the precise extent of variability in PASI measurements and its underlying causes remain unknown. Read More

    Drug survival of secukinumab for moderate-to-severe plaque psoriasis.
    Br J Dermatol 2018 Mar 23. Epub 2018 Mar 23.
    Kaiser Permanente Los Angeles Medical Center, Department of Dermatology, Los Angeles, CA, USA.
    We read with great interest the article "Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis" by Egeberg et al, particularly the finding that secukinumab had the poorest drug survival among the 5 biologics studied. It would be helpful to know what proportion of patients in this study were given 150 mg dosing, as this may explain the poor drug survival. In the United States, secukinumab is mainly prescribed at the 300 mg dosing, although 150 mg dosing may be acceptable in some patients per the prescribing information. Read More

    Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: Report of two cases.
    J Dermatol 2018 Mar 22. Epub 2018 Mar 22.
    Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
    Psoriasis is a chronic inflammatory skin disease mainly mediated by a T-helper cell subset, Th17 cells. Recently, increased levels of total serum immunoglobulin (Ig)E have been reported in a subset of psoriatic patients. Ustekinumab (UST) is one of the most commonly used biologic agents for the treatment of moderate to severe plaque psoriasis, and a previous report also documented effectiveness of UST for psoriatic patients with high serum IgE levels. Read More

    [Side effects of biologic therapies in psoriasis].
    Hautarzt 2018 Apr;69(4):290-297
    Hochschulklinik für Dermatologie, Venerologie und Allergologie, Immunologisches Zentrum, Städtisches Klinikum Dessau, Medizinische Hochschule Brandenburg Theodor Fontane, Auenweg 38, 06847, Dessau-Roßlau, Deutschland.
    Background: The introduction of biologics has revolutionized the treatment of moderate to severe plaque psoriasis. Due to the continuous expansion of biological therapies for psoriasis, it is particularly important to acknowledge efficacy and safety of the compounds not only in clinical trials but also in long-term registry-based observational studies.

    Aim: Typical side effects and significant risks of antipsoriatic biologic therapies considering psoriatic control groups are presented. Read More

    Brodalumab: A Review of Safety.
    Skin Therapy Lett 2018 03;23(2):1-3
    Probity Medical Research, Waterloo, ON Canada; K Papp Clinical Research, Waterloo, ON Canada.
    Interleukin (IL)-17 is important in the pathophysiology of psoriasis and has proven to be an effective therapeutic target. Brodalumab, the third commercially available IL-17 antagonist, was approved by the US FDA in February 2017 for the treatment of moderate-tosevere plaque psoriasis. As brodalumab enters the marketplace, it is imperative to investigate its safety profile. Read More

    Longitudinal study of the psoriasis-associated skin microbiome during therapy with ustekinumab in a randomized Phase 3b clinical trial.
    J Invest Dermatol 2018 Mar 17. Epub 2018 Mar 17.
    Departments of Dermatology and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address:
    Background: Plaque psoriasis, a chronic inflammatory disease primarily affecting the skin, is thought to have a multifactorial etiology, including innate immune system dysregulation, environmental triggers, and genetic susceptibility.

    Purpose: We sought to further understand the role of skin microbiota in psoriasis pathogenesis, as well as their response to therapy. We systematically analyzed dynamic microbiota colonizing psoriasis lesions and adjacent nonlesional skin in 114 patients prior to and during ustekinumab treatment in a Phase 3b clinical trial. Read More

    Psoriasis, chronic tonsillitis, and biofilms: Tonsillar pathologic findings supporting a microbial hypothesis.
    Ear Nose Throat J 2018 Mar;97(3):79-82
    Department of Dermatology, Drexel University College of Medicine, 219 N. Broad St., 4th Floor, Philadelphia, PA 19107, USA.
    Group A Streptococcus has been identified as a possible etiologic agent in psoriasis in epidemiologic, immunologic, immunopathologic, medical, and surgical studies. Tonsillectomy has been shown to provide considerable relief to 75% of patients with plaque psoriasis. Even with the substantial evidence supporting group A Streptococcus as a causative pathogen in psoriasis, it is an elusive pathogen because it is not culturable, nor does it exhibit any positive serologic evidence of its presence. Read More

    Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: results from UNCOVER-1, -2, and -3.
    J Am Acad Dermatol 2018 Mar 13. Epub 2018 Mar 13.
    Eli Lilly and Company, Indianapolis, IN, USA.
    Background: The impact of ixekizumab treatment for psoriasis on cardiovascular-related parameters in patients is unknown.

    Objective: We investigated cardiovascular-related parameters in patients with psoriasis treated with ixekizumab.

    Methods: In Phase 3 trials, patients with moderate-to-severe psoriasis were randomized and treated with placebo, ixekizumab, or etanercept during the induction period (Weeks 0-12; UNCOVER-1/-2/-3). Read More

    Elevated Gene Expression of Interleukin-32 Isoforms Alpha, Beta, Gamma, and Delta in the Peripheral Blood of Chronic Psoriatic Patients.
    Diseases 2018 Mar 14;6(1). Epub 2018 Mar 14.
    Department of Medical Biochemistry, College of Medicine, Qassim University, P.O. Box 6655, Buraidah 51452, Saudi Arabia.
    Inflammatory-mediated reactions have been implicated as contributors in a number of dermatological disorders, including psoriasis. However, the potential of interleukin (IL)-32 and its isoforms to contribute to the pathogenesis of psoriasis remains unexplored. This study was undertaken to investigate the role of IL-32 and its isoforms IL-32α, IL-32β, IL-32γ, and IL-32δ in the peripheral blood of psoriatic patients. Read More

    Clobetasol Emulsion Foam and Calcipotriene 0.005% Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis.
    J Drugs Dermatol 2018 Mar;17(3):342-346
    Optimizing combinations for psoriasis means asking patients to take control of their disease. It means balancing potency of steroids for the short-run to put out the fire and bring relief and maintaining the clearance for the long-run to reduce recurrence potential. Successful combinations are built on tolerability, ease of application, and the efficacy demonstrated by the synergy of the sum of the parts over being used separately. Read More

    A Systematic Review and Meta-Analysis of the Efficacy and Safety of the Interleukin (IL)-12/23 and IL-17 Inhibitors Ustekinumab, Secukinumab, Ixekizumab, Brodalumab, Guselkumab, and Tildrakizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
    J Dermatolog Treat 2018 Mar 13:1-37. Epub 2018 Mar 13.
    d Division of Dermatology , University of Arizona , Tucson , AZ.
    Objective: To systematically analyze the efficacy and safety of interleukin (IL)-12/23, IL-17, and selective IL-23 inhibitors in moderate to severe plaque psoriasis.

    Methods And Results: 24 randomized placebo-controlled trials were included. Compared to placebo, risk ratios (RR) of achieving PASI-75 and PGA/IGA 0/1 respectively were 20. Read More

    A review of neurologic complications of biologic therapy in plaque psoriasis.
    Cutis 2018 Jan;101(1):57-60
    Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, California, USA.
    The use of biologic medications has represented a great advancement in the treatment of moderate to severe plaque psoriasis and has improved patients' quality of life. Despite the increasing popularity of biologics, their neurological side effects have been a constant concern. Reports of demyelinating diseases associated with tumor necrosis factor α (TNF-α) inhibitors continue to accumulate. Read More

    Long-Term Optimization of Outcomes With Flexible Adalimumab Dosing in Patients With Moderate to Severe Plaque Psoriasis.
    J Eur Acad Dermatol Venereol 2018 Mar 10. Epub 2018 Mar 10.
    AbbVie Inc, North Chicago, IL, USA.
    Background: The recently updated dosing recommendation for adalimumab for moderate to severe plaque psoriasis states that patients with inadequate response to adalimumab every other week (EOW) after 16 weeks may benefit from an increase in dosing frequency to 40 mg every week (EW).

    Objective: To determine the long-term efficacy of adalimumab in patients with psoriasis with flexibility to escalate and de-escalate between EOW and EW dosing.

    Methods: Data from an open-label study in patients with psoriasis who had received adalimumab in phase 2/3 studies and their extensions were included. Read More

    Brodalumab: A Review in Moderate to Severe Plaque Psoriasis.
    Drugs 2018 Mar;78(4):495-504
    Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
    Brodalumab (Kyntheum) is a human anti-interleukin-17 receptor A (IL-17RA) monoclonal antibody available for use in patients with moderate to severe plaque psoriasis. In the phase III AMAGINE trials in this patient population, 12 weeks of induction therapy with subcutaneous brodalumab was superior to placebo in terms of the proportion of patients with ≥ 75% improvement in the Psoriasis Area and Severity Index score (PASI 75) and the proportion of patients with a static Physician Global Assessment score of 0 or 1. Brodalumab was also superior to ustekinumab for PASI 100 (i. Read More

    Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects.
    Basic Clin Pharmacol Toxicol 2018 Mar 6. Epub 2018 Mar 6.
    Merck & Co., Inc., Kenilworth, NJ, USA.
    Tildrakizumab, a high-affinity humanized IgG1k antibody that selectively binds interleukin (IL)-23 p19 subunit of cytokine IL-23 and neutralizes its function, is under investigation for treatment of moderate-to-severe chronic plaque psoriasis. The objective of this analysis was to assess the pharmacokinetics, bioavailability and safety/tolerability of single ascending doses of tildrakizumab after intravenous (IV) and subcutaneous (SC) dosing in healthy subjects. P05661 was a phase 1, single-dose, randomized, placebo-controlled study of tildrakizumab IV doses of 0. Read More

    Defining and treating moderate plaque psoriasis: a dermatologist survey.
    J Dermatolog Treat 2018 Mar 22:1-6. Epub 2018 Mar 22.
    c Southern California Dermatology , Santa Ana , CA , USA.
    Purpose: Patients with moderate plaque psoriasis are often undertreated and may experience unsatisfactory clinical outcomes. Undertreatment may stem partly from a lack of consensus on the definition of moderate psoriasis and appropriate treatments for patients with moderate disease severity.

    Materials And Methods: An online survey was conducted during October 2015 to determine how US dermatologists in the clinical setting define and treat moderate psoriasis. Read More

    Prospective, Observational, Non-Interventional, Multicentre Study on the Efficacy and Tolerability of a New Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients with Plaque Psoriasis under Daily Practice Conditions.
    Dermatology 2017 2;233(6):425-434. Epub 2018 Mar 2.
    Department of Dermatology, Venereology and Allergology and Outpatient Clinic of the Essen University Hospital, Essen, Germany.
    Background/aims: To assess the efficacy and tolerability of the new aerosol foam of calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g (Cal/BD foam, Enstilar®) in psoriasis vulgaris under daily practice conditions.

    Methods: 410 adult psoriasis patients (56% male) from 87 German sites were enrolled in a 4-week, open-label, prospective, non-controlled, observational, non-interventional study. Read More

    1 OF 74